Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

XTLB

XTL Biopharmaceuticals (XTLB)

XTL Biopharmaceuticals Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:XTLB
DatumZeitQuelleÜberschriftSymbolFirma
22/07/202422h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
12/06/202422h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/06/202415h20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/06/202415h15GlobeNewswire Inc.XTL Entered Definitive Agreement to Acquire The Social ProxyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
13/05/202416h32Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/03/202415h15GlobeNewswire Inc.XTL To Aquire The Social ProxyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
15/11/202316h29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/10/202322h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/10/202322h00GlobeNewswire Inc.XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/10/202322h00GlobeNewswire Inc.XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in IsraelNASDAQ:XTLBXTL Biopharmaceuticals Ltd
10/08/202315h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
16/05/202317h01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
23/02/202320h30Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
01/02/202315h53Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
24/08/202216h31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
30/03/202223h16Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
26/01/202218h43Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
19/01/202217h04Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
16/12/202123h17Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
24/11/202116h39Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
08/06/202112h05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
19/05/202117h40Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
19/05/202117h31Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
19/05/202117h26Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
07/01/202115h10Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
31/12/202017h12Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
25/11/202016h43Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
12/11/202016h00Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
24/08/202015h24Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
07/07/202014h04Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:XTLB

Kürzlich von Ihnen besucht

Delayed Upgrade Clock